Top 5 2nd Quarter Trades of OUP Management Co., LLC

Author's Avatar
insider
Jul 20, 2022
Article's Main Image

OUP Management Co., LLC recently filed their 13F report for the second quarter of 2022, which ended on 2022-06-30.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

50 Monument Road Bala Cynwyd, PA 19004

As of the latest 13F report, the guru’s equity portfolio contained 15 stocks valued at a total of $73.00Mil. The top holdings were CNTA(19.69%), PMVP(19.40%), and AVTE(12.99%).

According to GuruFocus data, these were OUP Management Co., LLC’s top five trades of the quarter.

IonQ Inc


OUP Management Co., LLC reduced their investment in NYSE:IONQ by 941,922 shares. The trade had a 9.15% impact on the equity portfolio. During the quarter, the stock traded for an average price of $7.17.

On 07/20/2022, IonQ Inc traded for a price of $4.73 per share and a market cap of $937.20Mil. The stock has returned -52.46% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, IonQ Inc has a price-book ratio of 1.52, a EV-to-Ebitda ratio of -13.35 and a price-sales ratio of 240.05.

Sera Prognostics Inc


The guru sold out of their 337,505-share investment in NAS:SERA. Previously, the stock had a 0.97% weight in the equity portfolio. Shares traded for an average price of $1.95 during the quarter.

On 07/20/2022, Sera Prognostics Inc traded for a price of $1.93 per share and a market cap of $59.70Mil. The stock has returned -80.41% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Sera Prognostics Inc has a price-book ratio of 0.47, a EV-to-Ebitda ratio of 1.12 and a price-sales ratio of 490.20.

Evolv Technologies Holdings Inc


OUP Management Co., LLC reduced their investment in NAS:EVLV by 238,145 shares. The trade had a 0.48% impact on the equity portfolio. During the quarter, the stock traded for an average price of $2.66.

On 07/20/2022, Evolv Technologies Holdings Inc traded for a price of $2.51 per share and a market cap of $359.88Mil. The stock has returned 0.00% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Evolv Technologies Holdings Inc has a price-book ratio of 1.24, a EV-to-Ebitda ratio of -19.55 and a price-sales ratio of 12.47.

Landos Biopharma Inc


OUP Management Co., LLC reduced their investment in NAS:LABP by 214,714 shares. The trade had a 0.24% impact on the equity portfolio. During the quarter, the stock traded for an average price of $0.92.

On 07/20/2022, Landos Biopharma Inc traded for a price of $0.7951 per share and a market cap of $32.01Mil. The stock has returned -92.87% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10. There is insufficient data to calculate the stock’s profitability rating.

In terms of valuation, Landos Biopharma Inc has a price-book ratio of 0.47, a EV-to-Ebitda ratio of 1.02 and a price-sales ratio of 1.65.

Centessa Pharmaceuticals PLC


During the quarter, OUP Management Co., LLC bought 595,724 shares of NAS:CNTA for a total holding of 2,937,615. The trade had a 4.07% impact on the equity portfolio. During the quarter, the stock traded for an average price of $9.11.

On 07/20/2022, Centessa Pharmaceuticals PLC traded for a price of $5 per share and a market cap of $470.21Mil. The stock has returned -76.55% over the past year.

GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Centessa Pharmaceuticals PLC has a price-book ratio of 1.00 and a EV-to-Ebitda ratio of 0.03.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

Request A Demo

Learn more about GuruFocus' key features, including All-In-One Screener, backtesting, 30-year financial, stock summary page, guru trades, insider trades, excel Add-in, google sheets and much more.

GuruFocus Screeners

Related Articles